Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000373342

Medchemexpress LLC I-138 | 2098211-50-6 | C26H23F3N6O | 1 ML
SDP

Catalog No. 5000373342
Encompass_Preferred

I-138 is an orally active, reversible inhibitor of USP1-UAF1, with an IC50 of 4.1 nM and Ki of 5.4 nM. It induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells. It is intended for research use only.

  • Eliminates USP1 self-lysis in HAP-1 USP1 WT and knockout cells
  • Induces monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells
  • Dose-dependently inhibits MDA-MB-436 cell viability
  • Results in USP1 inhibition and modest antitumor activity in mice bearing MDA-MB-436 tumors
  • Benefits BRCA1/2 mutant tumor inhibition in vivo when combined with Niraparib

Catalog No. 50-003-73342 Supplier Medchemexpress LLC Supplier No. HY15336510MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

I-138 is an orally active, reversible inhibitor of USP1-UAF1, with an IC50 of 4.1 nM and Ki of 5.4 nM. It induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells. It is intended for research use only.

  • Eliminates USP1 self-lysis in HAP-1 USP1 WT and knockout cells
  • Induces monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells
  • Dose-dependently inhibits MDA-MB-436 cell viability
  • Results in USP1 inhibition and modest antitumor activity in mice bearing MDA-MB-436 tumors
  • Benefits BRCA1/2 mutant tumor inhibition in vivo when combined with Niraparib

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.